The stable Q4 version of the VarSome API (stable-api.varsome.com) has now been updated from version 10.1.5 to version 10.2.6 with the data frozen as of the 4th November 2021.
This new version is now available for testing at staging-api.varsome.com.
The most recent version, used by VarSome itself, is always available at api.varsome.com.
Functional Changes
The major new feature in this API release is the classification of CNVs using an enhanced version of the ACMG guidelines for CNVs. The technical API documentation for this feature is available here, and here’s a simple example.
Please refer to the following release notes for changes to the overall system: 10.2 release note
Database Updates
The following databases have updated contents:
|
Database |
Old Version |
New Version |
Comment |
|
AACT |
14-Jul-2021 |
07-Sep-2021 |
|
|
Cancer Census |
v92 |
v94 |
|
|
Cancer HotSpots |
16-Feb-2021 |
10-Sep-2021 |
|
|
CBioPortal |
30-Mar-2021 |
17-Sep-2021 |
|
|
DGI |
15-Feb-2021 |
09-Sep-2021 |
|
|
FDA Pharmacogenomic BioMarkers |
16-Sep-2021 |
New |
|
|
Fusion GDB |
21-Sep-2021 |
New |
|
|
Genomics England PanelApp |
14-Jul-2021 |
13-Oct-2021 |
|
|
GHR Genes |
03-Aug-2020 |
20-Oct-2021 |
|
|
ICGC Somatic |
Release 28 |
Release 28 |
Records now contain additional information about the cancer name, cancer type & corresponding OncoTree codes. |
|
JAX CKB |
20-Jul-2021 |
20-Sep-2021 |
|
|
NCBI ClinVar |
13-Jul-2021 |
07-Oct-2021 |
|
|
NCBI ClinVar CNVs |
13-Jul-2021 |
07-Oct-2021 |
|
|
NIH GDC |
09-Apr-2021 |
13-Oct-2021 |
|
|
PharmGKB |
14-Jul-2021 |
16-Sep-2021 |
|
|
RefSeq transcripts |
206 |
208 |
|
|
Sanger DECIPHER |
13-Jul-2021 |
07-Oct-2021 |
|
|
Saphetor Known Pathogenic (clinically reported variants) |
21-Aug-2021 |
01-Nov-2021 |
|
|
Weill Cornell Medicine PMKB |
14-Apr-2020 |
19-Aug-2021 |
|
|
WUSTL CIViC |
13-Jul-2021 |
07-Oct-2021 |
Further Information and Support
An overview of the VarSome API is available here with more detailed information here.
Please contact us at the usual address support@varsome.com should you require any additional information or run into any major issues. As ever we look forward to your feedback and suggestions to improve our platform.
Submit a Comment